The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thu ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would become an oncology powerhouse with $8 billion blockbuster medications. Celgene share price surges 21% as Bristol-Myers Squibb (BMS) announces this acquisition. When the deal closes, Celgene shareholders would receive one BMS share, $50 in cash for each Celgene share, and one tradeable contingent value right for each share of Celgene. This contingent value right entitles its holder to gain a one-time potential payment of $9 in cash upon FDA approval of all 3 main medications of ozanimod (31 December 2020), liso-cel (31 December 2020) and bb2121 (31 March 2021).

BMS already owns a rich portfolio of blockbuster medications. These medications include the top-selling PD-1 checkpoint inhibitor Opdivo, the leukemia drug Sprycel, the melanoma drug Yervoy, the multiple-myeloma drugs Revlimid and Pomalyst, and the pancreatic cancer medicine Abraxane. These medications generate about $5.9 billion revenue in 2018Q3. These landmark medications position BMS as the market-share leader in immune-oncology and hematology.

The BMS specialty market niche and patent portfolio collectively create competitive moats for the new biopharma goliath in comparison to Johnson & Johnson, Merck, Pfizer, Roche, and Novartis etc.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Conor McGregor learns a major money lesson from LeBron James.

Daisy Harvey

2019-08-07 12:33:00 Wednesday ET

Conor McGregor learns a major money lesson from LeBron James.

Conor McGregor learns a major money lesson from LeBron James. This lesson suggests that James spends about $1.5 million on his own body each year. The $1.5

+See More

North Korean leader and president Kim Jong-Un seeks peaceful resolution and denuclearization on the Korean Peninsula.

Olivia London

2018-04-11 09:37:00 Wednesday ET

North Korean leader and president Kim Jong-Un seeks peaceful resolution and denuclearization on the Korean Peninsula.

North Korean leader and president Kim Jong-Un seeks peaceful resolution and denuclearization on the Korean Peninsula. When *peace* comes to shove, Asia

+See More

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Peter Prince

2019-01-07 18:42:00 Monday ET

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Neoliberal public choice continues to spin national taxation and several other forms of government intervention. The key post-crisis consensus focuses on go

+See More

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression.

Laura Hermes

2019-11-21 11:34:00 Thursday ET

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression.

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression. The current U.S. ec

+See More

World Economic Forum warns that artificial intelligence may destabilize the financial system.

Jonah Whanau

2018-08-19 10:34:00 Sunday ET

World Economic Forum warns that artificial intelligence may destabilize the financial system.

The World Economic Forum warns that artificial intelligence may destabilize the financial system. Artificial intelligence poses at least a trifecta of major

+See More

IMF chief economist Gita Gopinath indicates that competitive currency devaluation may be an ineffective solution to improving export prospects.

Fiona Sydney

2019-10-09 16:46:00 Wednesday ET

IMF chief economist Gita Gopinath indicates that competitive currency devaluation may be an ineffective solution to improving export prospects.

IMF chief economist Gita Gopinath indicates that competitive currency devaluation may be an ineffective solution to improving export prospects. In the form

+See More